Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model

Infection and Immunity

Volumn 79, Issue 3, 2011, Pages 986-996

  Farris, Christina M ^a,b,c   Morrison, Richard P ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; CHALMYDIA VACCINE; CHLAMYDIAL PROTEASE LIKE ACTIVITY FACTOR; MAJOR OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

CHLAMYDIA; CHLAMYDIACEAE INFECTION; GENITAL TRACT INFECTION; HUMAN; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION;

ANIMALS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; DISEASE MODELS, ANIMAL; HUMANS; MICE;

EID: 79952290901     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00881-10     Document Type: Short Survey

References (120)

1. Agger, E. M., et al. 2008. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3:e3116.
2. Baehr, W., et al. 1988. Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc. Natl. Acad. Sci. U. S. A. 85:4000-4004.
3. Barker, C. J., K. W. Beagley, L. M. Hafner, and P. Timms. 2008. In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB. Vaccine 26:1285-1296.
4. Barron, A. L., H. J. White, R. G. Rank, B. L. Soloff, and E. B. Moses. 1981. A new animal model for the study of Chlamydia trachomatis genital infections: infection of mice with the agent of mouse pneumonitis. J. Infect. Dis. 143:63-66.
5. Bell, S. D., Jr., R. L. Nichols, and N. A. Haddad. 1963. The immunology of the trachoma agent with a preliminary report on field trials on vaccine. Invest. Ophthalmol. 2:471-481.
6. Belland, R. J., et al. 2001. Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. Proc. Natl. Acad. Sci. U. S. A. 98:13984-13989.
7. Berry, L. J., et al. 2004. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72:1019-1028. (Pubitemid 38166684)
8. Blander, S. J., and A. J. Amortegui. 1994. Mice immunized with a chlamydial extract have no increase in early protective immunity despite increased inflammation following genital infection by the mouse pneumonitis agent of Chlamydia trachomatis. Infect. Immun. 62:3617-3624.
9. Brunham, R. C. 1999. Human immunity to chlamydiae, p. 211-238. In R. S. Stephens (ed.), Chlamydia: intracellular biology, pathogenesis, and immunity. American Society for Microbiology Press, Washington, DC.
10. Brunham, R. C., and J. Rey-Ladino. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5:149-161.
11. Brunham, R. C., D. J. Zhang, X. Yang, and G. McClarty. 2000. The potential for vaccine development against chlamydial infection and disease. J. Infect. Dis. 181(Suppl. 3):S538-S543.
12. Caldwell, H. D., and R. C. Judd. 1982. Structural analysis of chlamydial major outer membrane proteins. Infect. Immun. 38:960-968.
13. Caldwell, H. D., J. Kromhout, and J. Schachter. 1981. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31:1161-1176. (Pubitemid 11155484)
14. Carey, A. J., K. A. Cunningham, L. M. Hafner, P. Timms, and K. W. Beagley. 2009. Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice. Immunol. Cell Biol. 87:337-343.
15. CDC. 2009. Sexually transmitted disease surveillance, 2008. Centers for Disease Control and Prevention, Atlanta, GA.
16. Chaganty, B. K., et al. 2010. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine 28:2323-2329.
17. Champion, C. I., et al. 2009. A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One 4:e5409.
18. Cong, Y., et al. 2007. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine 25:3773-3780. (Pubitemid 46589760)
19. Cotter, T. W., K. H. Ramsey, G. S. Miranpuri, C. E. Poulsen, and G. I. Byrne. 1997. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect. Immun. 65: 2145-2152.
20. Crane, D. D., et al. 2006. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc. Natl. Acad. Sci. U. S. A. 103:1894-1899.
21. Cunningham, K. A., A. J. Carey, L. Hafner, P. Timms, and K. W. Beagley. 2011. Chlamydia muridarum major outer membrane protein-specific antibodies inhibit in vitro infection but enhance pathology in vivo. Am. J. Reprod. Immunol. 65:118-124.
22. Cunningham, K. A., A. J. Carey, N. Lycke, P. Timms, and K. W. Beagley. 2009. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. J. Reprod. Immunol. 81:34-38.
23. Darville, T., et al. 1997. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. Infect. Immun. 65:3065-3073.
24. Darville, T., et al. 2001. Mouse strain-dependent chemokine regulation of the genital tract T helper cell type 1 immune response. Infect. Immun. 69:7419-7424.
25. Darville, T., C. W. Andrews, Jr., J. D. Sikes, P. L. Fraley, and R. G. Rank. 2001. Early local cytokine profiles in strains of mice with different outcomes from chlamydial genital tract infection. Infect. Immun. 69:3556-3561.
26. Eko, F. O., et al. 2004. A novel recombinant multisubunit vaccine against Chlamydia. J. Immunol. 173:3375-3382. (Pubitemid 39142047)
27. Eko, F. O., et al. 2003. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine 21:1694-1703. (Pubitemid 36292160)
28. Ekong, E. E., et al. 2009. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol. Med. Microbiol. 55:280-291.
29. + T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect. Immun. 78:4374-4383.
30. Hafner, L., K. Beagley, and P. Timms. 2008. Chlamydia trachomatis infection: host immune responses and potential vaccines. Mucosal Immunol. 1:116-130.
31. Hansen, J., et al. 2008. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J. Infect. Dis. 198:758-767.
32. Hatch, T. P. 1999. Developmental biology, p. 29-67. In R. S. Stephens (ed.), Chlamydia: intracellular biology, pathogenesis, and immunity. American Society for Microbiology Press, Washington, DC.
33. Hickey, D. K., F. E. Aldwell, and K. W. Beagley. 2010. Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection. Vaccine 28:1668-1672.
34. Hickey, D. K., F. E. Aldwell, and K. W. Beagley. 2009. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections. Vaccine 27:6217-6225.
35. Hickey, D. K., et al. 2004. Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralizing IgA in the prostate. Vaccine 22:4306-4315.
36. Holmgren, J., C. Czerkinsky, K. Eriksson, and A. Mharandi. 2003. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21(Suppl. 2):S89-S95. (Pubitemid 36588654)
37. Huang, Z., et al. 2008. Structural basis for activation and inhibition of the secreted Chlamydia protease CPAF. Cell Host Microbe 4:529-542. (Pubitemid 352762954)
38. Ifere, G. O., et al. 2007. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J. Microbiol. Immunol. Infect. 40:188-200.
39. Igietseme, J. U., et al. 2000. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J. Immunol. 164:4212-4219. (Pubitemid 30215080)
40. Ito, J. I., and J. M. Lyons. 1999. Role of gamma interferon in controlling murine chlamydial genital tract infection. Infect. Immun. 67:5518-5521.
41. Johansson, E. L., L. Wassen, J. Holmgren, M. Jertborn, and A. Rudin. 2001. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect. Immun. 69:7481-7486.
42. Kari, L., et al. 2009. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J. Immunol. 182:8063-8070.
43. Kawa, D. E., J. Schachter, and R. S. Stephens. 2004. Immune response to the Chlamydia trachomatis outer membrane protein PorB. Vaccine 22: 4282-4286.
44. Kawa, D. E., and R. S. Stephens. 2002. Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity. J. Immunol. 168:5184-5191.
45. Kelly, K. A., and R. G. Rank. 1997. Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect. Immun. 65:5198-5208.
46. Kozlowski, P. A., et al. 2002. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 169:566-574. (Pubitemid 34686180)
47. Landers, D. V., K. Erlich, M. Sung, and J. Schachter. 1991. Role of L3T4-bearing T-cell populations in experimental murine chlamydial salpingitis. Infect. Immun. 59:3774-3777.
48. Lencer, W. I., and R. S. Blumberg. 2005. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 15:5-9.
49. Li, W., et al. 2007. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin. Vaccine Immunol. 14:1537-1544.
50. Li, W., et al. 2010. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge. Infect. Immun. 78:3942-3949.
51. Li, Z., D. Chen, Y. Zhong, S. Wang, and G. Zhong. 2008. The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infect. Immun. 76:3415-3428.
52. Li, Z., S. Wang, Y. Wu, G. Zhong, and D. Chen. 2008. Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice. Sci. China C Life Sci. 51:973-980.
53. McNeilly, C. L., et al. 2007. Expression library immunization confers partial protection against Chlamydia muridarum genital infection. Vaccine 25:2643-2655.
54. + Th1 response during Chlamydia trachomatis infection in mice and humans. Infect. Immun. 77:4168-4176.
55. Mestecky, J., Z. Moldoveanu, and M. W. Russell. 2005. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am. J. Reprod. Immunol. 53:208-214.
56. Molina, D. M., et al. 2010. Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine 28:3014-3024.
57. Morrison, R. P., and H. D. Caldwell. 2002. Immunity to murine chlamydial genital infection. Infect. Immun. 70:2741-2751.
58. Morrison, R. P., K. Feilzer, and D. B. Tumas. 1995. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect. Immun. 63:4661-4668.
59. Morrison, S. G., and R. P. Morrison. 2005. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175:7536-7542.
60. Morrison, S. G., and R. P. Morrison. 2000. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infect. Immun. 68:2870-2879.
61. + T cells. Infect. Immun. 69:2643-2649.
62. Morrison, S. G., and R. P. Morrison. 2005. The protective effect of antibody in immunity to murine chlamydial genital tract reinfection is independent of immunoglobulin A. Infect. Immun. 73:6183-6186.
63. + T cells. Infect. Immun. 68:6979-6987.
64. Murphey, C., et al. 2006. The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell. Immunol. 242:110-117.
65. Murthy, A. K., et al. 2009. A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge. FEMS Immunol. Med. Microbiol. 55:271-279.
66. Murthy, A. K., J. P. Chambers, P. A. Meier, G. Zhong, and B. P. Arulanandam. 2007. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect. Immun. 75:666-676.
67. Murthy, A. K., et al. 2006. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect. Immun. 74:6722-6729.
68. Murthy, A. K., M. N. Guentzel, G. Zhong, and B. P. Arulanandam. 2009. Chlamydial protease-like activity factor - insights into immunity and vaccine development. J. Reprod. Immunol. 83:179-184.
69. Nelson, D. E., et al. 2005. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc. Natl. Acad. Sci. U. S. A. 102:10658-10663.
70. Nigg, C. 1942. An unidentified virus which produces pneumonia and systemic infection in mice. Science 95:49-50.
71. O'Connell, C. M., R. R. Ingalls, C. W. Andrews, Jr., A. M. Scurlock, and T. Darville. 2007. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J. Immunol. 179:4027-4034.
72. Olivares-Zavaleta, N., W. Whitmire, D. Gardner, and H. D. Caldwell. 2010. Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine 28:1454-1462.
73. Olsen, A. W., M. Theisen, D. Christensen, F. Follmann, and P. Andersen. 2010. Protection against chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS One 5:e10768.
74. Pal, S., et al. 1999. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 17:459-465.
75. Pal, S., T. J. Fielder, E. M. Peterson, and L. M. de la Maza. 1994. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 62:3354-3362. (Pubitemid 24232121)
76. Pal, S., C. J. Luke, A. G. Barbour, E. M. Peterson, and L. M. de la Maza. 2003. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 21:1455-1465.
77. Pal, S., E. M. Peterson, and L. M. de la Maza. 2003. Induction of protective immunity against a Chlamydia trachomatis genital infection in three genetically distinct strains of mice. Immunology 110:368-375.
78. Pal, S., E. M. Peterson, and L. M. de la Maza. 1996. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect. Immun. 64:5341-5348.
79. Pal, S., E. M. Peterson, and L. M. de la Maza. 2005. Vaccination of newborn mice induces a strong protective immune response against respiratory and genital challenges with Chlamyida trachomatis. Vaccine 23:5351-5358. (Pubitemid 41579305)
80. Pal, S., E. M. Peterson, and L. M. de la Maza. 2005. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73:8153-8160.
81. Pal, S., E. M. Peterson, R. Rappuoli, G. Ratti, and L. M. de la Maza. 2006. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 24:766-775.
82. Pal, S., J. Rangel, E. M. Peterson, and L. de la Maza. 2000. Immunogenic and protective ability of the two developmental forms of Chlamydiae in a mouse model of infertility. Vaccine 18:752-761.
83. Pal, S., I. Theodor, E. Peterson, and L. M. de la Maza. 2001. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69:6240-6247.
84. Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza. 1997. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect. Immun. 65:3361-3369.
85. Peipert, J. F. 2003. Clinical practice. Genital chlamydial infections. N. Engl. J. Med. 349:2424-2430.
86. Perry, L. L., K. Feilzer, and H. D. Caldwell. 1997. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-g-dependent and -independent pathways. J. Immunol. 158:3344-3352.
87. Perry, L. L., et al. 1999. Differential sensitivity of distinct Chlamydia trachomatis isolates to IFN-gamma-mediated inhibition. J. Immunol. 162: 3541-3548.
88. Peterson, E. M., J. Z. You, V. Motin, and L. M. de la Maza. 1999. Intranasal immunization with Chlamydia trachomatis serovar E protects from a subsequent vaginal challenge with the homologous serovar. Vaccine 17:2901-2907.
89. Ramsey, K. H., J. L. DeWolfe, and R. D. Salyer. 2000. Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis. Infect. Immun. 68:7186-7189.
90. Ramsey, K. H., and R. G. Rank. 1991. Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines. Infect. Immun. 59:925-931.
91. Rank, R. G. 1999. Models of immunity, p. 239-295. In R. S. Stephens (ed.), Chlamydia: intracellular biology, pathogenesis, and immunity. American Society for Microbiology Press, Washington, DC.
92. Read, T. D., et al. 2000. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res. 28:1397-1406.
93. Roan, N. R., and M. N. Starnbach. 2008. Immune-mediated control of Chlamydia infection. Cell. Microbiol. 10:9-19.
94. Rockey, D. D., J. Wang, L. Lei, and G. Zhong. 2009. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev. Vaccines 8:1365-1377.
95. + type 2 rather than type 1 immune response that is not protective. Infect. Immun. 70:1097-1105.
96. Singh, S. R., et al. 2006. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine 24:1213-1224. (Pubitemid 43204503)
97. Starnbach, M. N., et al. 2003. An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response. J. Immunol. 171:4742-4749.
98. Stephens, R. S., et al. 1998. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282:754-759. (Pubitemid 28489390)
99. Stephens, R. S., R. Sanchez-Pescador, E. A. Wagar, C. Inouye, and M. S. Urdea. 1987. Diversity of Chlamydia trachomatis major outer membrane protein genes. J. Bacteriol. 169:3879-3885.
100. Sturdevant, G. L., et al. 2010. Frameshift mutations in a single novel virulence factor alter the in vivo pathogenicity of Chlamydia trachomatis for the female murine genital tract. Infect. Immun. 78:3660-3668.
101. + T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect. Immun. 63:3302-3308.
102. Su, H., K. Feilzer, H. D. Caldwell, and R. P. Morrison. 1997. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect. Immun. 65:1993-1999.
103. Su, H., et al. 1998. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J. Exp. Med. 188:809-818. (Pubitemid 28433408)
104. Su, H., R. Messer, W. Whitmire, S. Hughes, and H. D. Caldwell. 2000. Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for the development of live attenuated chlamydial vaccine strains. Infect. Immun. 68:192-196.
105. Sun, G., et al. 2007. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J. Bacteriol. 189:6222-6235. (Pubitemid 47378629)
106. Sun, G., S. Pal, J. Weiland, E. M. Peterson, and L. M. de la Maza. 2009. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 27:5020-5025.
107. Tavakoli, M., A. M. Craig, and M. Malek. 2002. An econometric analysis of screening and treatment of patients with suspected Chlamydia. Health Care Manag. Sci. 5:33-39. (Pubitemid 41450998)
108. Tuffrey, M., F. Alexander, W. Conlan, C. Woods, and M. Ward. 1992. Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein. J. Gen. Microbiol. 138:1707-1715.
109. Tuffrey, M., F. Alexander, and D. Taylor-Robinson. 1990. Severity of salpingitis in mice after primary and repeated inoculation with a human strain of Chlamydia trachomatis. J. Exp. Pathol. (Oxf.) 71:403-410. (Pubitemid 20175603)
110. Tuffrey, M., P. Falder, J. Gale, and D. Taylor-Robinson. 1986. Salpingitis in mice induced by human strains of Chlamydia trachomatis. Br. J. Exp. Pathol. 67:605-616. (Pubitemid 16035180)
111. van Ginkel, F. W., H. H. Nguyen, and J. R. McGhee. 2000. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg. Infect. Dis. 6:123-132.
112. Wang, J., et al. 2009. A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. Vaccine 27:2967-2980.
113. WHO. 1996. Global prevalence and incidence of selected curable sexually transmitted diseases: overviews and estimates. World Health Organization, Geneva, Switzerland.
114. WHO. 2001. Global prevalence and incidence of selected curable sexually transmitted infections: overviews and estimates. World Health Organization, Geneva, Switzerland.
115. WHO. 2007. Global strategy for prevention and control of sexually transmitted infections: 2006-2015. World Health Organization, Geneva, Switzerland.
116. Williams, D. M., B. G. Grubbs, E. Pack, K. Kelly, and R. G. Rank. 1997. Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis. Infect. Immun. 65:2876-2882.
117. Yen, T. Y., S. Pal, and L. M. de la Maza. 2005. Characterization of the disulfide bonds and free cysteine residues of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. Biochemistry 44:6250-6256.
118. Yu, H., X. Jiang, C. Shen, K. P. Karunakaran, and R. C. Brunham. 2009. Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models. J. Immunol. 182:1602-1608.
119. + T cells. Infect. Immun. 78:2272-2282.
120. Zhang, Y.-X., S. J. Stewart, and H. D. Caldwell. 1989. Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants. Infect. Immun. 57:636-638.